A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of AR9281 on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.
Epistemonikos ID: 289aecea6d6d35cca6e5c0494cb5372d7d320e4c
First added on: May 05, 2024